跳至主要内容
临床试验/NCT00422123
NCT00422123已完成3 期

A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Mania

AstraZeneca51 个研究点 分布在 1 个国家目标入组 447 人开始时间: 2007年1月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
AstraZeneca
入组人数
447
试验地点
51
主要终点
Change from baseline to final visit in the YMRS total score

研究概览

简要总结

The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Mania for 3 weeks.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Provision of written informed consent
  • Documented diagnosis of Bipolar Disorder, with most recent episode being manic or mixed
  • Inpatient hospital admission for the first 4 days of study treatment

排除标准

  • >8 mood episodes within the last 12 months
  • Use of prohibited medication
  • Substance or alcohol abuse or dependence
  • Current suicide risk or suicide attempt within last 6 months.

结局指标

主要结局

Change from baseline to final visit in the YMRS total score

次要结局

  • Change from baseline to each visit in YMRS score and changes of YMRS subscores and changes in MADRS.

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (51)

Loading locations...

相似试验